LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

LLY

1,075.36

-2.69%↓

JNJ

206.6

-0.54%↓

ABBV

227.76

+0.1%↑

UNH

330.04

+0.11%↑

AZN

92.73

-0.69%↓

Search

Revvity Inc

Geschlossen

BrancheGesundheitswesen

104.43 -0.29

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

103.83

Max

105.1

Schlüsselkennzahlen

By Trading Economics

Einkommen

-8.6M

47M

Verkäufe

-21M

699M

KGV

Branchendurchschnitt

54.418

79.874

EPS

0.4

Dividendenrendite

0.28

Gewinnspanne

6.675

Angestellte

11,000

EBITDA

-14M

181M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+6.15% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.28%

2.31%

Nächstes Ex-Dividendendatum

16. Jan. 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

976M

12B

Vorheriger Eröffnungskurs

104.72

Vorheriger Schlusskurs

104.43

Nachrichtenstimmung

By Acuity

16%

84%

56 / 374 Ranking in Healthcare

Revvity Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

28. Nov. 2025, 15:29 UTC

Wichtige Markttreiber
Akquisitionen, Fusionen, Übernahmen

China's Jiangxi Copper Rejected by SolGold in $1 Billion Takeover Approach

28. Nov. 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. Nov. 2025, 19:59 UTC

Market Talk

Oil Futures Settle Lower in Slow Black Friday Trade -- Market Talk

28. Nov. 2025, 19:47 UTC

Market Talk

U.S. Natural Gas Lifted By Cold Weather Outlook -- Market Talk

28. Nov. 2025, 18:16 UTC

Market Talk

Global Equities Roundup: Market Talk

28. Nov. 2025, 18:16 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. Nov. 2025, 18:08 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

28. Nov. 2025, 18:08 UTC

Market Talk

Messy Canada GDP Data Still Seen as Cause for Optimism in 2026 -- Market Talk

28. Nov. 2025, 17:48 UTC

Market Talk

Bank of Canada May Revise Up Inflation Projections After GDP Data -- Market Talk

28. Nov. 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

28. Nov. 2025, 16:50 UTC

Akquisitionen, Fusionen, Übernahmen

Week's Best: Sieg's Stature at Citi Grows -- Barrons.com

28. Nov. 2025, 15:51 UTC

Market Talk

Canada Household Spending Edges Lower -- Market Talk

28. Nov. 2025, 15:33 UTC

Market Talk

Crude Futures Gain as U.S. Market Reopens -- Market Talk

28. Nov. 2025, 15:21 UTC

Market Talk

Gold Rises on U.S. Rate-Cut Bets After CME Outage -- Market Talk

28. Nov. 2025, 15:13 UTC

Market Talk

Dollar Recovers Slightly as Investors Already Price in Fed Rate Cut -- Market Talk

28. Nov. 2025, 15:11 UTC

Market Talk

Global Equities Roundup: Market Talk

28. Nov. 2025, 15:11 UTC

Market Talk

Canadian National Railway Showing Positive Trend Going Into 2026 -- Market Talk

28. Nov. 2025, 14:51 UTC

Market Talk

Canada GDP Report Masks Fragile State of Economy -- Market Talk

28. Nov. 2025, 14:41 UTC

Market Talk

Canada's GDP Level Pulled Higher by 'Eye-Opening' Revisions -- Market Talk

28. Nov. 2025, 14:37 UTC

Market Talk

U.S. Natural Gas Futures Rise As Temperatures Drop -- Market Talk

28. Nov. 2025, 14:33 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. Nov. 2025, 14:33 UTC

Market Talk

Steep Import Drop Fuels Surprise Lift in Canada GDP -- Market Talk

28. Nov. 2025, 14:20 UTC

Market Talk

Too Much Noise in Canada's Surprise 3Q GDP Gain -- Market Talk

28. Nov. 2025, 14:10 UTC

Market Talk

Canadian Nowcast Came Closest to Predicting Surprise 3Q Strength -- Market Talk

28. Nov. 2025, 13:39 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

28. Nov. 2025, 13:39 UTC

Market Talk

Canada Trade Data Could Face Larger-Than-Normal Revisions -- Market Talk

28. Nov. 2025, 13:36 UTC

Market Talk

Canada's Economy Expands More Than Expected -- Market Talk

28. Nov. 2025, 13:29 UTC

Market Talk

CME Outage Sowing Chaos Across Markets, Trade Nations Says -- Market Talk

28. Nov. 2025, 13:27 UTC

Market Talk

Russia-Ukraine Peace Efforts to Have Little Impact on Oil Fundamentals -- Market Talk

28. Nov. 2025, 13:19 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Revvity Inc Prognose

Kursziel

By TipRanks

6.15% Vorteil

12-Monats-Prognose

Durchschnitt 111.1 USD  6.15%

Hoch 125 USD

Tief 100 USD

Basierend auf 11 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Revvity Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

11 ratings

8

Buy

3

Halten

0

Sell

Stimmung

By Acuity

56 / 374 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Revvity Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat